Elanco Animal Health Reports Second Quarter 2026 Results
Elanco Animal Health (NYSE: ELAN) reported Q2 2026 revenue of $1.368B, up 10% year over year (8% organic constant currency). Adjusted EPS was $0.34 and adjusted EBITDA $288M (21.2% margin). It raised full-year 2026 guidance, including revenue to $5.09B-$5.14B and adjusted EBITDA to $1.01B-$1.035B, and targeted year-end net leverage of about 3.0x.
How this was made
The 30-second read
Why it matters
The key tradable change is the simultaneous upward revision to revenue, profitability (Adjusted EBITDA), and EPS, alongside a tighter year-end net leverage target, indicating improved financial flexibility.
Market read
Traders can update models immediately using the raised FY 2026 targets and leverage guidance, which typically drive valuation multiples for profitable growth stories.
What to watch
The excerpt does not include the specific Q3 guidance numbers or any risk commentary on regulatory, competitive, or supply constraints that could limit upside follow-through.
Background
Elanco reported Q2 2026 results and updated full-year 2026 guidance, highlighting innovation-led growth from Zenrelia and Credelio Quattro and improved leverage.
Ticker impact
Elanco raised full-year revenue, Adjusted EBITDA, and Adjusted EPS guidance, plus improved year-end net leverage target to about 3.0x.
Likely positive near-term reaction as traders re-rate FY growth and margin outlook; follow-through depends on Q3 guidance details not included in the excerpt.
The article is a primary earnings and guidance update with multiple raised targets (top line, EBITDA, EPS) and a specific balance-sheet metric (net leverage target).
Market effects
Supports sentiment for animal health peers by reinforcing demand durability in pets and protein and continued innovation-driven share gains.
U.S. Pet Health strength (up 11% organic) may buoy investor focus on U.S. vet-channel performance.
Global growth drivers cited (U.S. and Europe share gains for Zenrelia and Credelio Quattro) reinforce multinational demand resilience.
Counterpoint
Raised guidance could already be partially priced in; margin expansion may be sensitive to inventory cost inflation and marketing investment pace.
Key entities
- public_companyElanco Animal Health Incorporated
NYSE-listed animal health company reporting Q2 results and raising FY 2026 guidance.
- productZenrelia
Elanco’s newest blockbuster cited as the largest contributor to global growth.
- productCredelio Quattro
Broad-spectrum product cited for accelerating share gains in Q2.
